Capadenoson

Drug Profile

Capadenoson

Alternative Names: BAY 68-4986

Latest Information Update: 07 May 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare
  • Class Ischaemic heart disorder therapies; Nitriles; Pyridines; Thiazoles
  • Mechanism of Action Adenosine A1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Angina pectoris; Atrial fibrillation

Most Recent Events

  • 28 Mar 2011 No development reported - Phase-II for Atrial fibrillation in Germany (PO)
  • 13 Apr 2007 Data presented at the 56th Annual Scientific Session of the American College of Cardiology (ACC-2007) added to the adverse events and Ischaemic Heart Disease therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top